Sun Pharmaceutical has posted a strong set of results for the second quarter of fiscal 2009, driven by improved performance by both its Indian branded drug and US generics businesses.
US drugmaker Par Pharmaceuticals is wielding the axe at its generics division, cutting 190 jobs and refocusing its R&D efforts on the completion of its current roster of product candidates
Pharmaceutical companies on both sides of the Atlantic are facing a particularly difficult time over the next 12 to 18 months, according to a report by financial research and analysis company Moody’s.
A new packaging artwork management system will help cost-sensitive generics producers cut launch times and make increased use of outsourcing, according to US developer Precise Data (PD).
The US Food and Drug Administration has resorted to a legal
challenge against India's Ranbaxy Laboratories in an ongoing
investigation into the sale of substandard drugs.
The FDA has issued US drug maker Scientific Laboratories with an
injunction preventing it from producing drugs until
manufacturing operations are brought up to code.
India's Dr Reddy's Laboratories has just announced the signing of a
definitive agreement to buy the US pharmaceutical contract
manufacturing business of chemicals giant BASF.
Three of India´s large pharmaceutical manufacturers, Dr Reddy's,
Ranbaxy Laboratories and Shilpa Medicare have just announced new
merger and acquisition (M&A) deals.
It seems that the ghost of the US Food and Drug Administration
(FDA) probe has stopped haunting MDS Pharma as the firm posted
encouraging financial results in the third quarter.
India-based Dr Reddy's Laboratories has boosted its revenue by 168
per cent for the 2006 year, fuelled by a strengthening position in
the international market.
The US Biotechnology Industry Organisation (BIO) has fuelled even
further the ongoing debate over the potential approval path for
follow-on biologics in the country with the release of a white
paper this week that stressed that 'generic'...
US Food and Drug Administration (FDA) has until April 2007 to reply
to a Citizen's Petition (CP) filed by Orchid Chemicals in response
to accusations of 'evergreening' related to Wyeth's re-formulated
Zosyn (piperacillin/tazobactam),...
MDS has announced it will help its customers confirm or repeat
analyses done at its contract research facilities in Quebec, after
the Food and Drug Administration (FDA) urged some drug makers to
retest products because of concerns...
Merck KGaA last week confirmed that it is considering selling off
its generics division, prompting mass speculation over potential
buyers within the industry.
Intertek has broadened its portfolio to offer outsourced analysis of biologics as well as small molecules by purchasing Alta Laboratories, for $25m (€18.8m).
Dr. Reddy's Laboratories has announced the inauguration of its
seventh finished dosage plant in India, reflecting the country's
unprecedented growth as a generic pharmaceuticals manufacturer.
The battle for the acquisition that will form the world's third
biggest generic drugmaker has intensified, with Iceland's Actavis
making a new offer for Croatian drug manufacturer Pliva that
surpasses that of US pharmaceutical...
As it consolidates its manufacturing operations in the US, Watson
Pharmaceuticals has received a warning letter from the US Food and
Drug Administration (FDA) accusing it of using the wrong
ingredients in the production of capsules,...
Vintage Pharmaceuticals, a generic drugmaker with plants in North
Carolina and Alabama, has pleaded guilty to 19 felony counts of
producing adulterated drugs and introducing them into interstate
commerce.
Canadian contract manufacturer Patheon saw pre-tax profits remain
idle in the second quarter of 2006, leaving it struggling to find
ways to boost profitability.
Spending up to $400m (€330m), Indian drugmaker Ranbaxy has ended
the week with three acquisitions of European generic companies
under its belt, hoping a strong foothold in Europe will help it
offset its declining fortunes in the US.
Looking to establish itself in Eastern Europe, French drug maker
Sanofi-Aventis has bought a 24.9 per cent stake in Czech generic
drug firm Zentiva for $514.7m (€430m).
As a fever of consolidation continues to sweep the generics market,
Iceland's Actavis Group has offered to buy out Croatian rival Pliva
in a proposal which values it at $1.6bn (€1.31bn) and aims to
create the world's third...
New legislation has given UK company Accentus the green light to
use its novel predictive crystallisation technology to discover and
market variations of patented drugs without infringing the original
patent.
Pliva released its financial results for the first nine months of
2005, which revealed a net loss of $34 million, as the drug maker
tries to recover from its loss-making drug launch in the US. This
is despite posting higher revenues...
New findings may have significant implications for the growing
generics drugs industry, by challenging previous assumptions that
all formulations of the same active pharmaceutical ingredient (API)
are therapeutically equivalent.
US consumers could have saved $20 billion (€16.6 billion) in 2004
and even more could be saved in future years by using more generic
drugs, according to a new report by Express Scripts.
Actavis's $810 million (€677 million) cash acquisition of
Alpharma's US and international generic drugs division is part of
the firm's strategy to become one of the global leaders in the
sector.
Sandoz, the generics subsidiary of Swiss pharmaceutical company
Novartis, is rumoured to be planning an acquisition in India in a
move that would give it back the top slot in the sector.
Troubled generic drug manufacturer Able Laboratories has conceded
defeat in its bid to get products back onto the market and elected
to sell off the assets of the business.
Indian pharmaceutical company Matrix Laboratories is aiming to buy
a 22 per cent controlling stake in Belgium's Docpharma in what is
the largest overseas acquisition yet in India's drug industry,
reports Phil Taylor.
Perrigo, a US manufacturer of nonprescription drugs and nutritional
products, has completed its acquisition of Agis Industries, the
second largest drug company in Israel, for $818m.
Novartis, the Swiss pharmaceutical giant has acquired two companies
as it aims to expand its generics drug portfolio and increase its
presence in the generics sector. The strategic move is expected to
make Novartis the world's...
The Indian pharmaceutical sector has begun its seismic shake-up
following the introduction of new laws granting patent protection
to medicines on 1 January.
Pharmaceutical companies are set to face stiff competition, as
generic forms of best-selling biologic drugs will capture a
significant market share. The expiration of drug patents, which
expire within the next few years, opens up...
Codexis has signed a research collaboration agreement with generics
company Teva Pharmaceutical Industries to develop improved
processes for the manufacturing of a currently marketed fermented
pharmaceutical product.
Israeli generics and active pharmaceutical ingredients (API)
company Teva Pharmaceutical Industries announced yet another
acquisition earlier today, this time for Pfizer's Italian generic
pharmaceutical marketing company Dorom.
India's Dr Reddy's Laboratories has acquired a US company that
brings in a proprietary drug delivery technology that could be
applied across a whole range of dermatological products.
The global generics industry is growing at such a rate that it can
now support billion dollar companies, with activities crossing into
active pharmaceutical ingredient (API) production and R&D. This
shift in the sector - from...
Israel's Teva plans to buy Sicor in a €2.9bn deal that will create
a powerhouse in generic pharmaceuticals and active pharmaceutical
ingredient manufacturing.
The pharmaceutical industry is facing the possibility of earlier
generic competition for its branded products from 18 August, when
new legislation in the USA comes into effect.
Novartis has agreed to pay GlaxoSmithKline a royalty on sales of a
generic version of GSK's antibiotic Augmentin
(amoxicillin/clavulanate) sold in the USA as AmoxC.